With US reclassifying medical marijuana, is it now legal across the country?

The Trump administration reclassified state-licensed medical marijuana from Schedule I to Schedule III, a major federal policy shift that should ease regulation and allow businesses to deduct federal tax expenses. The order does not legalize recreational marijuana, but it legitimizes medical cannabis programs in 40 states and expedites DEA registration for producers and distributors. It also reduces legal and research barriers for state-licensed medical marijuana operators, with potential implications for retail operations in states that sell to medical patients.

Analysis

The immediate economic winner is not the plant itself but the licensed medical channel’s cost structure. Reclassifying to Schedule III should improve after-tax cash flow meaningfully for operators with large corporate overhead, because federal expense deductibility converts a low-margin, cash-tax-constrained business into something closer to a normal consumer healthcare distribution model. That is a bigger multiple driver than the headline “legalization” narrative: even a modest uplift in EBITDA margins can re-rate the entire group if lenders and equity investors start underwriting to cleaner free cash flow.

Second-order beneficiaries are the picks-and-shovels names that monetize compliance, testing, packaging, software, security, and interstate-adjacent supply chain services. The real optionality is on multi-state operators that already have medical footprints in large states; they can capture the tax benefit immediately, while recreational-only exposure remains trapped by federal illegality and banking friction. That creates a dispersion trade: medical-heavy names should outperform pure adult-use operators over the next 1-3 quarters, especially where state medical labels are already embedded inside broader retail stores.

The main risk is a “sell the news” response if investors extrapolate too much into a slow federal process. Schedule III does not remove banking, interstate commerce, or full legalization constraints, so the valuation uplift should be capped until the late-June hearing produces a clearer path. Politically, a change in DOJ posture or adverse court challenge could delay implementation for months, while the biggest upside surprise would be broader descheduling, which would sharply expand TAM but also intensify competition and compress margins.

Key Decisions for Investors

• Long basket of MSOs with high medical mix for 1-3 months; favor names with large state-licensed medical revenue and existing tax-deductibility upside. Risk/reward: 15-25% upside on margin re-rating, 10-15% downside if the market fades the announcement.
• Pair trade: long medical-heavy cannabis operators / short adult-use-heavy operators for the next quarter. Thesis: tax relief accrues immediately to the medical channel while recreational-only economics remain policy-constrained.
• Buy near-dated call spreads on the most levered multi-state operators ahead of the late-June hearing. Use spreads, not outright calls, because the policy path is iterative and headline risk is high.
• Add selective exposure to compliance/service vendors in the cannabis ecosystem on any pullback; these names have less regulatory headline beta and may see a slower but more durable re-rating as institutional customers normalize spending.